Jo-Fen Liu

Dr. Jo-Fen Liu

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2025 in Archives of Disease in Childhood
Verified
Journal Article
Open access
JLJo-Fen Liu
Jo-Fen Liu
DSDhurgshaarna Shanmugavadivel
Dhurgshaarna Shanmugavadivel
ABAshley Ball-Gamble
Ashley Ball-Gamble
DWDavid Walker
David Walker
Background: Children and young people (CYP) with bone tumours often experience lengthy intervals prior to diagnosis that can lead to increased morbidity and mortality. Early diagnosis is key to optimising treatment options and long-term outcomes. This review aims to describe symptomatology at diagnosis, in order to develop interventions to accelerate diagnosis. Methods: A literature search of MEDLINE and EMBASE was conducted for studies published between January 2008 and May 2023, reporting signs and symptoms in CYP with bone tumours. Pooled proportions of symptoms and signs were calculated. Results: 16 studies (1452 patients; 492 osteosarcoma and 932 Ewing’s sarcoma) were included in the analysis. The most prevalent symptoms were pain (64%, 95% CI 52% to 75%) and swelling (22%, 95% CI 6% to 42%). Other symptoms included fever, pain and swelling, history of trauma, pathological fracture, palpable mass, functional limitation, increased volume and limp. Subanalysis identified differences in symptom clusters: osteosarcoma more frequently presented with a history of trauma, pathological fracture, pain on weight-bearing, pain worse at night, pain at rest and weight loss. Ewing’s sarcoma was associated with fever, functional limitation and a palpable mass. Conclusions: These data highlight the differences in presentations between osteosarcoma and Ewing sarcoma, which may account for differences in survival and outcome. This will be used to inform professional and public health interventions through the Child Cancer Smart campaign to accelerate diagnosis for all. This review also highlights the need for a renewed research focus to identify patients earlier in the disease development as a strategy to improve the current static outcomes.

27 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
DSDurgagauri H. Sabnis
Durgagauri H. Sabnis
JLJo-Fen Liu
Jo-Fen Liu
LSLucy Simmonds
Lucy Simmonds
SBSophie Blackburn
Sophie Blackburn
RGRichard G. Grundy
Richard G. Grundy
ECElizabeth Coyle
Elizabeth Coyle
Paediatric ependymomas are aggressive, treatment-resistant tumours with a tendency towards relapse, consistent with a sub-population of therapy-resistant cancer stem cells. These cells are believed to derive from brain lipid binding protein (BLBP)-expressing radial glia, hence we proposed that BLBP may be a marker for ependymoma therapy resistance. BLBP protein expression correlated with reduced overall survival (OS) in patients from two trials (CNS9204, a chemotherapy-led infant trial—5 y OS 45% vs. 80%, p = 0.011—and CNS9904, a radiotherapy-led trial—OS 38% vs. 85%, p = 0.002). All ependymoma cell lines examined by qRT-PCR expressed BLBP, with expression elevated in stem cell-enriched neurospheres. Modulation of BLBP function in 2D and 3D assays, using either peroxisome proliferator activated receptor (PPAR) antagonists or BLBP’s fatty acid substrate docosahexaneoic acid (DHA), potentiated chemotherapy response and reduced cell migration and invasion in ependymoma cell lines. BLBP is therefore an independent predictor of poor survival in paediatric ependymoma, and treatment with PPAR antagonists or DHA may represent effective novel therapies, preventing chemotherapy resistance and invasion in paediatric ependymoma patients.

16 February 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
DSDhurgshaarna Shanmugavadivel
Dhurgshaarna Shanmugavadivel
JLJo-Fen Liu
Jo-Fen Liu
ABAshley Ball-Gamble
Ashley Ball-Gamble
APAngela Polanco
Angela Polanco
KVKavita Vedhara
Kavita Vedhara
Shalini OjhaShalini Ojha
Shalini Ojha
Introduction Childhood cancer is diagnosed in 400 000 children and young people (CYP) aged 0–19 years worldwide annually. In the UK, a child’s cumulative cancer risk increases from 1 in 4690 from birth to aged 1, to 1 in 470 by age 15. Once diagnosed, access to treatments offers survival to adulthood for over 80%. Tumour diagnoses are at a later stage and mortality is higher when compared with those in other parts of Europe. This means higher risk, more intensive therapies for a cure. Some CYPs are known to experience delays to diagnosis which may further contribute to poor outcomes. This study aims to understand the current pathway of childhood cancer referrals and diagnosis and quantify diagnostic intervals in the UK. Methods and analysis This is a prospective multicentre observational study including all tertiary childhood cancer treatment centres in the UK. CYP (0–18 years) with a new diagnosis of cancer over the study period will be invited to participate. Data will be collected at initial diagnosis and 5 years after diagnosis. Data will include demographic details, clinical symptoms, tumour location, stage and clinical risk group. In addition, key diagnostic dates and referral routes will be collected to calculate the diagnostic intervals. At 5 years’ follow-up, data will be collected on refractory disease, relapse and 1-year and 5-year survival. Population characteristics will be presented with descriptive analyses with further analyses stratified by age, geographical region and cancer type. Associations between diagnostic intervals/delay and risk factors will be explored using multiple regression and logistic regression. Ethics The study has favourable opinion from the York and Humber, Leeds West REC (19/YH/0416). Dissemination Results will be presented at academic conferences, published in peer-reviewed journals and disseminated through public messaging in collaboration with our charity partners through a national awareness campaign (ChildCancerSmart). Study registration researchregistry.com (researchregistry5313).

27 May 2025 in The Lancet Regional Health - Europe
Verified
Journal Article
Open access
DSDhurgshaarna Shanmugavadivel
Dhurgshaarna Shanmugavadivel
JLJo-Fen Liu
Jo-Fen Liu
TRTimothy Ritzmann
Timothy Ritzmann
ABAshley Ball-Gamble
Ashley Ball-Gamble
APAngela Polanco
Angela Polanco
DWDavid Walker
David Walker
Childhood cancer is a global disease burden, with early diagnosis a priority. We quantified diagnostic intervals and referral routes for children and young people (CYP 0–18 years) diagnosed with cancer in the UK. All CYP diagnosed between September 2020–March 2023 were eligible. Demographic, referral, and symptom data were collected prospectively. Patient interval (PI), diagnostic interval (DI), and total diagnostic interval (TDI) were calculated. 1957 CYP (mean age 7.4 years, 55% male, 78% white) participated. Median PI, DI, and TDI were 1.1 (IQR 0.1–4.0; range 0–164), 1.7 (IQR 0.4–5.9; range 0–310), and 4.6 weeks (IQR 2.0–11.4; range 0–310), respectively. Intervals were unaffected by sex, ethnicity or deprivation index (IMD). Median TDI was longest in 15–18 years (8.7 weeks, IQR 3.0–17.4) and bone tumours (12.6 weeks, IQR 6.6–23.4) and shortest in under ones (3.7 weeks, IQR 1.0–8.1) and renal tumours (2.3 weeks, IQR 0.9–5.0). 74% (n = 1438) had 1–3 pre-diagnostic healthcare contacts; 67% (n = 1312) presented emergently, with a median of 4.0 (range 0–26) symptoms. CYP with Langerhans Cell Histiocytosis were most likely to have ≥4 visits when compared with leukaemia (adjusted OR 7.48, 95% CI 3.54–15.82), followed by central nervous system, bone, and soft tissue tumours. This study highlights equal access to diagnosis for sex, ethnicity and IMD, but disparities for age and diagnostic groups. These data will inform professional and public health strategies and health policy to accelerate diagnosis for all. National Institute for Health and Social Care Research (NIHR) DRF-2018-11-ST2-055.

30 November 2015 in Paediatrics and Child Health
Verified
Journal Article
Closed access
PDF file
DSDhurgshaarna Shanmugavadivel
Dhurgshaarna Shanmugavadivel
DWDavid Walker
David Walker
JLJo-Fen Liu
Jo-Fen Liu
SWSophie Wilne
Sophie Wilne

17 October 2023 in Archives of Disease in Childhood
Verified
Journal Article
Open access
PDF file
JLJo-Fen Liu
Jo-Fen Liu
DSDhurgsharna Shanmugavadivel
Dhurgsharna Shanmugavadivel
ABAshley Ball-Gamble
Ashley Ball-Gamble
ASAngela Stewart
Angela Stewart
DWDavid Walker
David Walker
Objectives To assess public awareness of the risks and symptoms of cancer in children, teenagers, and young adults (CTYA) aged 18 years, with 26% having children aged 6–15 in their households. Questions covered perception about cumulative cancer risk, confidence in recognising signs and symptoms, recognition and perceived urgency of classical signs and symptoms. Results Only 32% of respondents felt confident in recognising CTYA cancer signs and symptoms. Symptoms deemed to require medical assessment within 48 hours by over 50% of participants included seizures/fits, blood in urine or stool, and persistent vomiting. All symptoms except one were selected for assessment within 3 months. On average, respondents identified 10.6 out of 42 classical signs and symptoms. The most recognised symptoms included lump, swelling in pelvis, testicle or breast (46%), blood in urine or stool (44%), changes to moles (43%), lump/swelling in the chest wall or armpits (41%) and weight loss (40%). The least recognised symptoms were early/late puberty (10%), developmental delay in children aged <2 years (11%) and slow growth (13%), with 8%, 2% and 6%, respectively, perceiving no need to discuss them with a doctor. Conclusions Public awareness of childhood cancer risks and symptoms is substantially lower compared with adult cancer awareness in Great Britain. These findings indicate knowledge and awareness gaps among the general public, highlighting the need for a child cancer awareness campaign.